John Scarlett

The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc.

Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ.

Part of Pfizer Inc., Sensus Drug Development Corp. is a company that develops drugs to treat endocrine disorders. The company is based in San Antonio, TX. The company was founded by John A. Scarlett, Richard J. Hawkins. Sensus Drug Development was acquired by Pharmacia Corp. on March 07, 2001.

Part of Novo Nordisk A/S, Novo Nordisk Pharmaceutical Industries, Inc. is a company that manufactures pharmaceutical preparations. The company is based in Clayton, NC.

Greenwich Pharmaceuticals, Inc. is an American company that specializes in commercial physical research.

Ortho-McNeil Pharmaceutical LLC manufactures pharmaceutical products. Its products include ditropan, elmiron, modicon, otho cept and ortho novum etc. The company was founded in 1993 and is headquartered in Raritan, NJ.

Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA